Kinnate Biopharma Inc. (KNTE) — Financial statements
Income statement, balance sheet, and cash flow for Kinnate Biopharma Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.80↑32.3% | 0.60↑391.1% | 0.12↑48.2% | 0.08 | 0.00 | |
| Gross Profit | -0.80↓32.3% | -0.60↓391.1% | -0.12↓48.2% | -0.08 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 91↑3.0% | 88↑31.2% | 67↑129.7% | 29↑226.5% | 9 | |
| General & Administrative Expenses | 0.00↓100.0% | 30↑32.4% | 23↑239.2% | 7↑121.3% | 3 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 27↓9.6% | 30↑32.4% | 23↑239.2% | 7↑121.3% | 3 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 0.35↑7060.0% | -0.01 | 0.00 | |
| Operating Expenses | 118↓0.3% | 119↑31.5% | 90↑150.3% | 36↑199.7% | 12 | |
| Total Costs & Expenses | 119↑0.4% | 119↑31.5% | 90↑150.3% | 36↑199.7% | 12 | |
| Operating Results | ||||||
| Operating Income | -119↓0.4% | -119↓31.5% | -90↓150.3% | -36↓199.7% | -12 | |
| Depreciation & Amortization | 0.80↑32.3% | 0.60↑391.1% | 0.12↑48.2% | 0.08↓51.7% | 0.17 | |
| EBITDA | -118↓0.2% | -118↓31.0% | -90↓150.5% | -36↓199.0% | -12 | |
| EBIT | -119↓0.4% | -119↓31.5% | -90↓150.3% | -36 | 0.00 | |
| Interest & Other Income | ||||||
| Net Interest Income | 9 | 0.00↓100.0% | 0.35↑42.0% | 0.25↑469.8% | 0.04 | |
| Interest Income | 9 | 0.00↓100.0% | 0.35↑42.0% | 0.25↑469.8% | 0.04 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 6↑182.6% | 2↑546.6% | 0.35↑45.0% | 0.24↑458.1% | 0.04 | |
| Income Before Tax | -113↑3.1% | -116↓29.5% | -90↓151.0% | -36↓198.8% | -12 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.04 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -113↑3.1% | -116↓29.5% | -90↓151.0% | -36↓199.9% | -12 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -113↑1.2% | -114↓27.5% | -89↓152.3% | -35↓197.1% | -12 | |
| Bottom-Line Net Income | -113↑3.1% | -116↓29.5% | -90↓151.0% | -36↓199.9% | -12 | |
| EPS (Basic) | -2.42↑6.6% | -2.59↓26.3% | -2.05↓153.1% | -0.81↓189.3% | -0.28 | |
| EPS (Diluted) | -2.42↑6.6% | -2.59↓26.3% | -2.05↓153.1% | -0.81↓189.3% | -0.28 | |
| Weighted Average Shares | 47↑5.7% | 44↑1.1% | 44↑0.3% | 43↑0.3% | 43 | |
| Weighted Average Diluted Shares | 47↑5.7% | 44↑1.1% | 44↑0.3% | 43↑0.3% | 43 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.